Enlivex Therapeutics’ (ENLV) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Enlivex Therapeutics (NASDAQ:ENLV) in a research report released on Friday, Benzinga reports. The firm currently has a $6.00 price objective on the stock.

Separately, EF Hutton Acquisition Co. I raised shares of Enlivex Therapeutics to a strong-buy rating in a research note on Tuesday, August 27th.

Enlivex Therapeutics Price Performance

Shares of NASDAQ ENLV opened at $1.64 on Friday. The company’s 50 day simple moving average is $1.34 and its 200 day simple moving average is $1.79. Enlivex Therapeutics has a fifty-two week low of $1.15 and a fifty-two week high of $4.59. The firm has a market capitalization of $34.23 million, a P/E ratio of -1.18 and a beta of 1.03.

Enlivex Therapeutics (NASDAQ:ENLV) last announced its quarterly earnings data on Friday, August 30th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.06. Sell-side analysts expect that Enlivex Therapeutics will post -0.7 EPS for the current fiscal year.

Institutional Investors Weigh In On Enlivex Therapeutics

A hedge fund recently bought a new stake in Enlivex Therapeutics stock. XTX Topco Ltd acquired a new position in shares of Enlivex Therapeutics Ltd. (NASDAQ:ENLV) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 24,820 shares of the company’s stock, valued at approximately $35,000. XTX Topco Ltd owned approximately 0.12% of Enlivex Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 1.02% of the company’s stock.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.